← Back
Data updated: Jun 28, 2026
DYAX CORP.
Biotech Pharmaceuticals
DYAX CORP. is a biotechnology company with 2 FDA-approved products.
2009
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Biologics
FDA Novel Drug Designations
(2018) 1 Novel 1 Orphan 1 Breakthrough 1 Priority Review 1 Fast Track
See 1 novel approval →
2018 TAKHZYRO (LANADELUMAB-FLYO) Orphan · Breakthrough · Priority Review · Fast Track
DYAX CORP.'s Key Drugs
DYAX CORP.'s core commercial portfolio centers on TAKHZYRO — its most strategically important drugs approved in the last 15 years.
DYAX CORP.'s Recent FDA Approvals
New NDA/BLA approvals for DYAX CORP. over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
DYAX CORP.'s Therapeutic Areas
Disease areas where DYAX CORP. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
DYAX CORP. Pipeline Snapshot
Active clinical trials for DYAX CORP. across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TAKHZYRO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2009-12-01
- Latest
- 2023-02-03
- Applications
- 2